Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe safety and efficacy of Dapaglifozin in adults
patients with a systemic right ventricle (congenitally corrected transposition of the great
arteries or transposition of the great arteries following arterial switch procedure) and
impaired systolic function of the systemic right ventricle.